Clinical Research Directory
Browse clinical research sites, groups, and studies.
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
Sponsor: The First Affiliated Hospital of Xiamen University
Summary
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.
Official title: Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Neuroendocrine Carcinoma
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-12-01
Completion Date
2026-12-31
Last Updated
2026-03-09
Healthy Volunteers
No
Interventions
Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT
Participants will undergo DLL3-Targeted PET/CT imaging for the evaluation of tumor lesions. Imaging findings will be compared with conventional imaging modalities as part of the study analysis.
Locations (1)
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China